ERBB2 and metastatic neoplasm: Studies have investigated the use of blood based biomarkers, such as carcinoembryonic antigen and carbohydrate antigen 15–3 for primary diagnosis and the detection of metastatic disease (100–105), with others examining the correlation between serum HER2 concentration and tumor HER2 status (106–109).